Trending

COPD

Mylan launches Advair generic at 70% discount in US

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the

X

Mylan launches Advair generic at 70% discount in US

https://pharmaphorum.com/news/mylan-launches-advair-generic-at-70-discount-in-us/

AZ’s new COPD inhaler Bevespi Aerosphere approved in EU

AZ’s new COPD inhaler Bevespi Aerosphere approved in EU

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic

X

AZ’s new COPD inhaler Bevespi Aerosphere approved in EU

https://pharmaphorum.com/news/astrazeneca-copd-bevespi-aerosphere/

AZ COPD drug fails to match GSK rival after disappointing launch

AZ COPD drug fails to match GSK rival after disappointing launch

AstraZeneca has said it is analysing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in

X

AZ COPD drug fails to match GSK rival after disappointing launch

https://pharmaphorum.com/news/az-copd-drug-fails-match-gsk-rival/

GSK’s Nucala unlikely to get COPD use after panel vote

GSK’s Nucala unlikely to get COPD use after panel vote

FDA due to make decision in September

X

GSK’s Nucala unlikely to get COPD use after panel vote

https://pharmaphorum.com/news/gsks-nucala-unlikely-to-get-copd-use-after-panel-vote/

NICE restricts use of antibiotics in draft COPD guidance

NICE restricts use of antibiotics in draft COPD guidance

NICE has published draft guidance restricting use of antibiotics in patients with chronic obstructive pulmonary disease (COPD), as

X

NICE restricts use of antibiotics in draft COPD guidance

https://pharmaphorum.com/news/nice-restricts-use-of-antibiotics-in-draft-copd-guidance/

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca’s respiratory biologic fails again in COPD

AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.

X

AstraZeneca’s respiratory biologic fails again in COPD

https://pharmaphorum.com/news/astrazenecas-respiratory-biologic-copd/

Blow for AZ as late stage COPD trial fails

Blow for AZ as late stage COPD trial fails

GSK also hopes to get IL-5 drug approved in COPD

X

Blow for AZ as late stage COPD trial fails

https://pharmaphorum.com/news/blow-for-az-as-late-stage-copd-trial-fails/

Boehringer Ingelheim rolls-out COPD digital adherence programme

Boehringer Ingelheim rolls-out COPD digital adherence programme

Boehringer Ingelheim has expanded access to a digital adherence programme that helps COPD patients take their medicines as

X

Boehringer Ingelheim rolls-out COPD digital adherence programme

https://pharmaphorum.com/news/boehringer-copd-digital-adherence/

FDA approves expanded use for GSK’s COPD triple therapy

FDA approves expanded use for GSK’s COPD triple therapy

GSK is aiming to revive its respiratory drugs franchise

X

FDA approves expanded use for GSK’s COPD triple therapy

https://pharmaphorum.com/news/fda-approves-expanded-use-for-gsks-copd-triple-therapy/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com